Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medios AGMEDOF 88 3-Year EPS without NRI Growth Rate is -11.20% as of Jun. 2026. GuruFocus rates MEDOF with a GF Score™ of 88/100 and a GF Value™ of $77.37. The stock has 2 warning signs investors should review. Among 102 Medical Distribution companies, Medios AG ranks worse than 70.59% on this metric.
During the past 12 months, Medios AG's average EPS without NRI Growth Rate was 1.10% per year.
During the past 3 years, the average EPS without NRI Growth Rate was -11.20% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 9.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Medios AG was 31.20% per year. The lowest was -42.30% per year. And the median was 2.70% per year.
Medios AG (OTCPK:MEDOF) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Medios AG 3-Year EPS without NRI Growth Rate Related Terms
MEDOF vs MCK, COR, CAH: 3-Year EPS without NRI Growth Rate Comparison
For the Medical Distribution subindustry, Medios AG's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medios AG 3-Year EPS without NRI Growth Rate vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Medios AG's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Medios AG's 3-Year EPS without NRI Growth Rate falls into.
Medios AG 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of -11.20% mean?
Medios AG (MEDOF) has a 3-Year EPS without NRI Growth Rate of -11.20% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Medios AG and its competitors. According to the industry distribution chart, Medios AG ranks #72 out of 102 companies in the Medical Distribution industry, placing it in the top 70.6%.
Is Medios AG's 3-Year EPS without NRI Growth Rate too high?
Medios AG's current 3-Year EPS without NRI Growth Rate is -11.20%. Based on the distribution chart, Medios AG ranks #72 out of 102 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Medios AG has a GF Score™ of 88/100, reflecting its overall financial health beyond just this single metric.
How does Medios AG's 3-Year EPS without NRI Growth Rate compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Medios AG ranks #72 out of 102 companies for 3-Year EPS without NRI Growth Rate. This places Medios AG in the lower half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 3.10. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Medical Distribution company?
The median 3-Year EPS without NRI Growth Rate among Medical Distribution companies is 3.10, based on 102 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Medios AG and its competitors. For the Medical Distribution industry, the median 3-Year EPS without NRI Growth Rate is 3.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medios AG's current 3-Year EPS without NRI Growth Rate is -11.20%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medios AG stock overvalued right now?
Medios AG (MEDOF) has a current 3-Year EPS without NRI Growth Rate of -11.20%. The stock's GF Value™ is $77.37, compared to a current price of $50.00 — trading 35.4% below its estimated fair value. The current 3-Year EPS without NRI Growth Rate is -11.20%. Medios AG's overall GF Score™ is 88/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Medios AG (MEDOF), the current 3-Year EPS without NRI Growth Rate is -11.20% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medios AG (MEDOF) Overvalued in 2026?
Based on GuruFocus' analysis, Medios AG stock appears to be undervalued.
The current stock price of $50.00 is trading 35.4% below its estimated GF Value™ of $77.37.
Key valuation signals for MEDOF:
3-Year EPS without NRI Growth Rate: -11.20%
GF Value™: $77.37 vs. price of $50.00 (35.4% below fair value)
No single metric tells the full story. See the MEDOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medios AG is engaged as a wholesaler for pharmaceutical medicinal products. The operating segments of the company includes: Patient-Specific Therapies: This area includes the compounding of medications on behalf of pharmacies in Germany. Pharmaceautical Supply: Medios is speciality pharma supplier company in germany, producing it own production facilities, hospitals, and Pharmacies. International Business: It includes all business and activities happening in international business.
88GF Score
Get the complete analysis for MEDOF
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEDOF has been successfully added to your 
